Literature DB >> 19666639

Perioperative anticoagulation for patients with mechanic heart valve(s) undertaking pacemaker implantation.

Min Cheng1, Wei Hua, Keping Chen, Jielin Pu, Xiaoqing Ren, Xinran Zhao, Zhimin Liu, Fangzheng Wang, Xin Chen, Shu Zhang.   

Abstract

AIMS: This study was to evaluate perioperative anticoagulation therapy in patients with mechanic heart valve(s) undergoing pacemaker implantation. METHODS AND
RESULTS: A total of 109 patients with mechanical heart valve(s) undertaking pacemaker implantation were studied. Fifty-one patients with warfarin suspended 3 days before surgery were classified into Group 1 and 58 patients with warfarin suspended <3 days or not at all into Group 2. The perioperative incidence of complications was compared. Suspension of warfarin<3 days before surgery was associated with a higher incidence of excessive haemorrhage (16/51 vs. 5/58, P=0.003). Patients with pocket haematoma were more likely to have been treated with post-operation heparin (60% vs. 17.3%, P=0.032). In 42 patients treated with proposed protocol of perioperative anticoagulation, no pocket haematoma or embolism occurred.
CONCLUSIONS: A minimum of 3 days cessation of warfarin prior to surgery is preferred. Low-molecular-weight heparin should not be used for at least 3 days post-surgery. We propose that the protocol of perioperative anticoagulation be a suspension of warfarin not <3 days with low-molecular-weight heparin bridging stopped 12 h before surgery, and warfarin rather than low-molecular-weight heparin initiated immediately after surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666639     DOI: 10.1093/europace/eup212

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  2 in total

1.  Risk factors associated with early- versus late-onset implantable cardioverter-defibrillator infections.

Authors:  Muhammad R Sohail; Salwa Hussain; Katherine Y Le; Chadi Dib; Christine M Lohse; Paul A Friedman; David L Hayes; Daniel Z Uslan; Walter R Wilson; James M Steckelberg; Larry M Baddour
Journal:  J Interv Card Electrophysiol       Date:  2011-03-02       Impact factor: 1.900

2.  Safety of anticoagulation with uninterrupted warfarin vs. interrupted dabigatran in patients requiring an implantable cardiac device.

Authors:  Shivanshu Madan; Purushothaman Muthusamy; Katie L Mowers; Darryl A Elmouchi; Bohuslav Finta; Andre J Gauri; Alan K Woelfel; Timothy D Fritz; Alan T Davis; Nagib T Chalfoun
Journal:  Cardiovasc Diagn Ther       Date:  2016-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.